Further, the transcriptome analysis showed that the HD treatment caused abnormal hepatic lipid metabolism via suppressing the PPAR, insulin and adipocytokine signaling pathways, which may be another potential cause of the low growth in the HD group. Here, PPARA is linked to Huntington disease.